Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.C04 and Pembrolizumab in Head and Neck Cancer
NCT06054477Phase 2Terminated
- Sponsor
- Alentis Therapeutics
- Start
- Oct 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of ALE-C04 in head and neck squamous cell carcinoma (HNSCC), sponsored by Alentis Therapeutics. Started Oct 2023; status: terminated.
02
Drugs
ALE-C04
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06054477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054477.